NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers

CompletedN/A

Sponsor: Rutgers, The State University of New Jersey

Conditions: Parkinson, Parkinson Disease, Genetic Predisposition, GBA Gene Mutation, Cognitive Decline

Countries: United States

Every year, approximately 9,000 Parkinson disease (PD) patients undergo deep brain stimulator (DBS) placement into the subthalamic nucleus (STN-DBS). Studies suggest that PD patients with mutations in the glucocerebrosidase (GBA) gene are at high risk for cognitive impairment and approximately 10-17% of subjects undergoing DBS carry GBA mutations. There may be an interaction between STN-DBS, which also impairs cognitive function, and GBA, resulting in worsened cognitive function. This project will 1) determine the relationship between GBA mutation status and post-operative STN-DBS cognitive function, 2) broaden genotype-phenotype relationships of GBA mutation carriers and 3) provide scientific knowledge regarding the longitudinal cognitive effects of DBS in GBA mutation carriers through repeated neuropsychological testing.

Eligibility overview

Sex: ALL

Age: 30 Years to 75 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Parkinson's disease
* onset of symptoms under age 60
* at least 5 years of disease
* with OR without deep brain stimulation

Exclusion Criteria:

* dementia

Locations (1)

New Brunswick, New Jersey, United States